Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 3, 2015, Pages 281-288

  Sattler, Fred R ^a   He, Jiaxiu ^b   Letendre, Scott ^c   Wilson, Cara ^f   Sanders, Chelsea ^c   Heaton, Robert ^d   Ellis, Ronald ^e   Franklin, Donald ^d   Aldrovandi, Grace ^g   Marra, Christina M ^h   Clifford, David ⁱ   Morgello, Susan ^j   Grant, Igor ^d   McCutchan, J Allen ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

abdominal obesity; global deficit score; HIV associated neurocognitive disorder; inflammation and immune activation; sCD14; sCD40L

Indexed keywords

ADIPONECTIN; CD14 ANTIGEN; CD163 ANTIGEN; CD40 LIGAND; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; CYTOKINE;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BRAIN FUNCTION; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AIDS DEMENTIA COMPLEX; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; YOUNG ADULT;

ADULT; AGED; AIDS DEMENTIA COMPLEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; YOUNG ADULT;

EID: 84923642128     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000458     Document Type: Article

References (60)

1. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75: 2087-2096.
2. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007; 45: 174-182.
3. McCombe JA, Vivithanaporn P, Gill MJ, et al. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Med. 2013; 14: 99-107.
4. Grant I, Franklin DR Jr, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014; 82: 2055-2062.
5. Valcour V, Sithinamsuwan P, Letendre S, et al. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2011; 8: 54-61.
6. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012; 78: 485-492.
7. Yaffe K, Haan M, Blackwell T, et al. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study. J Am Geriatr Soc. 2007; 55: 758-762.
8. Panza F, Solfrizzi V, Logroscino G, et al. Current epidemiological approaches to the metabolic-cognitive syndrome. J Alzheimers Dis. 2012; 30(suppl 2): S31-S75.
9. Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on aging. Neurobiol Aging. 2011; 32: 1932-1941.
10. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307: 491-497.
11. Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 2014; 160: 517-525.
12. Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001; 15: 2001-2010.
13. Sattler F. Body habitus changes related to lipodystrophy. Clin Infect Dis. 2003; 36(suppl 2): S84-S90.
14. Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007; 30: 113-119.
15. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004; 292: 2237-2242.
16. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts. Alzheimer Dis Assoc Disord. 2007; 21: 167-171.
17. Dik MG, Jonker C, Comijs HC, et al. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care. 2007; 30: 2655-2660.
18. Roberts RO, Geda YE, Knopman DS, et al. Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord. 2010; 24: 11-18.
19. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998; 83: 847-850.
20. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011; 121: 2111-2117.
21. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793-1801.
22. Apovian CM, Bigornia S, Mott M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008; 28: 1654-1659.
23. Zanni MV, Burdo TH, Makimura H, et al. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf). 2012; 77: 385-390.
24. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA. 2012; 308: 379-386.
25. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12: 1365-1371.
26. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013; 39: 633-645.
27. Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol. 1994; 98: 369-374.
28. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292: E740-E747.
29. Roncon-Albuquerque R Jr, Moreira-Rodrigues M, Faria B, et al. Attenuation of the cardiovascular and metabolic complications of obesity in CD14 knockout mice. Life Sci. 2008; 83: 502-510.
30. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and Coagulation but not t-cell activation Predict non-AIDS-Defining Morbid Events during Suppressive antiretroviral treatment. J Infect Dis 2014; 210: 1248-1259.
31. Blackstone K, Moore DJ, Franklin DR, et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol. 2012; 26: 894-908.
32. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004; 26: 307-319.
33. Sattler F, Bhasin S, He J, et al. Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci. 2011; 66: 122-129.
34. Blodget E, Shen C, Aldrovandi G, et al. Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One. 2012; 7: e42624.
35. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and blood Institute Scientific Statement. Circulation. 2005; 112: 2735-2752.
36. Wright S. Correlation and causation. J Agric Res. 1921; 20: 557-585.
37. Bentler PM, Bonnett DG. Significance tests of goodness-of-fit in the analysis of covariance structures. Psychol Bull. 1980; 88: 586-606.
38. Byrd DA, Fellows RP, Morgello S, et al. Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr. 2011; 58: 154-162.
39. Salemi J, Obregon DF, Cobb A, et al. Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener. 2011; 6: 3.
40. Sui Z, Sniderhan LF, Schifitto G, et al. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol. 2007; 178: 3226-3236.
41. Omari KM, Dorovini-Zis K. CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium. J Neuroimmunol. 2003; 134: 166-178.
42. Omari KM, Chui R, Dorovini-Zis K. Induction of beta-chemokine secretion by human brain microvessel endothelial cells via CD40/CD40L interactions. J Neuroimmunol. 2004; 146: 203-208.
43. Ramirez SH, Fan S, Dykstra H, et al. Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis. J Neurosci. 2010; 30: 9454-9464.
44. Avison MJ, Nath A, Greene-Avison R, et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol. 2004; 10: 223-232.
45. Sitati E, McCandless EE, Klein RS, et al. CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J Virol. 2007; 81: 9801-9811.
46. Poggi M, Engel D, Christ A, et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler Thromb Vasc Biol. 2011; 31: 2251-2260.
47. Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008; 1: 36-43.
48. Ishikawa M, Vowinkel T, Stokes KY, et al. CD40/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia/reperfusion. Circulation. 2005; 111: 1690-1696.
49. Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A. 2003; 100: 8514-8519.
50. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol. 2004; 173: 3916-3924.
51. Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci. 2005; 25: 1788-1796.
52. Suh HS, Zhao ML, Choi N, et al. TLR3 and TLR4 are innate antiviral immune receptors in human microglia: role of IRF3 in modulating antiviral and inflammatory response in the CNS. Virology. 2009; 392: 246-259.
53. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008; 3: e2516.
54. Valcour VG, Sacktor NC, Paul RH, et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii aging with HIV cohort. J Acquir Immune Defic Syndr. 2006; 43: 405-410.
55. Panza F, Frisardi V, Seripa D, et al. Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res. 2011; 8: 492-509.
56. Cassol E, Misra V, Morgello S, et al. Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J Neuroimmune Pharmacol. 2013; 8: 1087-1097.
57. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormonereleasing hormone on cognitive function in adults with mild cognitive impairment and Healthy older adults: results of a controlled trial. Arch Neurol. 2012; 69: 1420-1429.
58. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004; 3: 169-178.
59. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol. 2001; 177: 125-134.
60. Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004; 63: 1187-1192